SCHEMBL6841555

SCHEMBL6841555

CC1CC2(CCN(C/C=C/c3ccccc3)CC2)C(=O)c2ccccc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.47
MAPT P10636 1/20 0.47
OPRM1 P35372 2/20 0.44
OPRK1 P41145 2/20 0.44
OPRD1 P41143 3/20 0.43
LMNA P02545 2/20 0.43
CYP3A4 P08684 2/20 0.43
HIF1A Q16665 2/20 0.43
SIGMAR1 Q99720 2/20 0.43
CHRM3 P20309 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
GMNN O75496 1/20 0.43
ABCB11 O95342 1/20 0.43
CHRM2 P08172 1/20 0.43
CHRM4 P08173 1/20 0.43
HTR1A P08908 1/20 0.43
CHRM5 P08912 1/20 0.43
ADRA2A P08913 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6840766 0.78 SIGMAR1 (0.60) OPRM1SIGMAR1DRD2HTR2AHTR2B
SCHEMBL6840846 0.78 SIGMAR1 (0.54) OPRM1OPRK1SIGMAR1DRD2HTR2A
SCHEMBL6836322 0.77 SIGMAR1 (0.64) ALDH1A1MAPTSIGMAR1DRD2HTR2A
SCHEMBL6836323 0.77 SIGMAR1 (0.64) ALDH1A1MAPTSIGMAR1DRD2HTR2A
SCHEMBL6836341 0.76 SIGMAR1 (0.52) OPRM1OPRK1SIGMAR1DRD2HTR2A
SCHEMBL6841154 0.76 SIGMAR1 (0.58) OPRM1OPRK1OPRD1SIGMAR1DRD2
SCHEMBL6841664 0.75 SIGMAR1 (0.63) OPRM1OPRK1OPRD1SIGMAR1DRD2
SCHEMBL7586310 0.75 SIGMAR1 (0.58) ALDH1A1MAPTSIGMAR1DRD2HTR2A
SCHEMBL6836327 0.72 KDM4E (0.45) ALDH1A1MAPTLMNASIGMAR1GAA
SCHEMBL6843243 0.70 SIGMAR1 (0.55) ALDH1A1LMNASIGMAR1GAADRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1235808-A2 TRICYCLIC ANALGESICS WARNER-LAMBERT COMPANY (US) 2002-09-04 EP claimed
WO-2000075116-A2 TRICYCLIC ANALGESICS WARNER-LAMBERT COMPANY (US) 2000-12-14 WO claimed
US-20040266802-A1 Tricyclic analgesics CALVET ALAIN (US) 2004-12-30 US disclosed
EP-1235808-A2 TRICYCLIC ANALGESICS WARNER-LAMBERT COMPANY (US) 2002-09-04 EP disclosed
WO-2000075116-A2 TRICYCLIC ANALGESICS WARNER-LAMBERT COMPANY (US) 2000-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040266802-A1 Tricyclic analgesics OPRM1, OPRL1, OPRD1 ALDH1A1 683/4885MAPT 2178/4885OPRM1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.